DMAC vs TMO · $157.4M cap vs P/E 24, rev $44.56B
DiaMedica Therapeutics Inc (DMAC) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
DMAC currently screens at market cap $157.4M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the DMAC and TMO stock pages for the full models.
Not investment advice.